Literature DB >> 28692708

Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder.

Chao Zhang1, De-Cai Tian1, Chun-Sheng Yang1, Bin Han1, Jing Wang1, Li Yang1, Fu-Dong Shi1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28692708      PMCID： PMC5822186          DOI： 10.1001/jamaneurol.2017.1336

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  6 in total

Review 1.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

2.  Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.

Authors:  Jessica L Halliley; Christopher M Tipton; Jane Liesveld; Alexander F Rosenberg; Jaime Darce; Ivan V Gregoretti; Lana Popova; Denise Kaminiski; Christopher F Fucile; Igor Albizua; Shuya Kyu; Kuang-Yueh Chiang; Kyle T Bradley; Richard Burack; Mark Slifka; Erika Hammarlund; Hao Wu; Liping Zhao; Edward E Walsh; Ann R Falsey; Troy D Randall; Wan Cheung Cheung; Iñaki Sanz; F Eun-Hyung Lee
Journal:  Immunity       Date:  2015-07-14       Impact factor: 31.745

3.  The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

Authors:  Kirsten Neubert; Silke Meister; Katrin Moser; Florian Weisel; Damian Maseda; Kerstin Amann; Carsten Wiethe; Thomas H Winkler; Joachim R Kalden; Rudolf A Manz; Reinhard E Voll
Journal:  Nat Med       Date:  2008-06-08       Impact factor: 53.440

4.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

Review 5.  Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.

Authors:  Valentina Damato; Amelia Evoli; Raffaele Iorio
Journal:  JAMA Neurol       Date:  2016-11-01       Impact factor: 18.302

6.  Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica.

Authors:  Norio Chihara; Toshimasa Aranami; Shinji Oki; Takako Matsuoka; Masakazu Nakamura; Hitaru Kishida; Kazumasa Yokoyama; Yoshiyuki Kuroiwa; Nobutaka Hattori; Tomoko Okamoto; Miho Murata; Tatsushi Toda; Sachiko Miyake; Takashi Yamamura
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240
  6 in total
  19 in total

Review 1.  Emerging therapeutic targets for neuromyelitis optica spectrum disorder.

Authors:  Lukmanee Tradtrantip; Nithi Asavapanumas; Alan S Verkman
Journal:  Expert Opin Ther Targets       Date:  2020-03-02       Impact factor: 6.902

Review 2.  Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review.

Authors:  Marco Vabanesi; Serena Marita Lazzarin; Giordano Cecchetti; Raffaella Fazio; Giovanna Franca Fanelli; Maria Antonietta Volonté; Angela Genchi; Antonino Giordano; Vittorio Martinelli; Sergio Colombo; Paolo Beccaria; Milena Mucci; Jacopo Peccatori; Massimo Filippi; Fabio Minicucci
Journal:  J Neurol       Date:  2020-06-13       Impact factor: 4.849

Review 3.  [Treatment of antibody-mediated encephalomyelitis : Strategies for the treatment of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease].

Authors:  Ilya Ayzenberg; Ingo Kleiter
Journal:  Nervenarzt       Date:  2021-03-30       Impact factor: 1.214

Review 4.  Autoantibodies in neurological disease.

Authors:  Harald Prüss
Journal:  Nat Rev Immunol       Date:  2021-05-11       Impact factor: 53.106

Review 5.  Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics.

Authors:  Laura Cacciaguerra; Paola Tortorella; Maria A Rocca; Massimo Filippi
Journal:  Neurotherapeutics       Date:  2021-04-28       Impact factor: 6.088

Review 6.  Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases.

Authors:  Panos Stathopoulos; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-02-18       Impact factor: 6.088

Review 7.  The B cell immunobiology that underlies CNS autoantibody-mediated diseases.

Authors:  Bo Sun; Melanie Ramberger; Kevin C O'Connor; Rachael J M Bashford-Rogers; Sarosh R Irani
Journal:  Nat Rev Neurol       Date:  2020-07-28       Impact factor: 44.711

Review 8.  Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.

Authors:  Jan Traub; Silke Häusser-Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 9.  Emerging small-molecule treatments for multiple sclerosis: focus on B cells.

Authors:  Aaron Gregson; Kaitlyn Thompson; Stella E Tsirka; David L Selwood
Journal:  F1000Res       Date:  2019-03-01

10.  Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis.

Authors:  Yong-Won Shin; Soon-Tae Lee; Tae-Joon Kim; Jin-Sun Jun; Kon Chu
Journal:  Ann Clin Transl Neurol       Date:  2018-03-23       Impact factor: 4.511
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.